GON.F Geron Corporation

Healthcare Biotechnology Frankfurt Exchange
0.8982 EUR
Close of Nov 13, 2026
0.8156 1.63
Market cap
EUR 579M
P/E
-
P/B
2.75x
ROE
-11.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GON.F undervalued?

Graham number

The Graham number of Geron Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Geron Corporation fundamental analysis

No fundamental analysis for Geron Corporation yet.

Geron Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment …

Full company profile